Patient´s own immune cells instead of industrial drugs
Individual cancer treatment is a representative application for iREM
Our immune system – individual and unique like a fingerprint – is designed to serve the needs of one’s own organism. If we want to take advantage of it in the treatment of various diseases, this can only be done on the basis of a unique, personal immunotherapy.
A life in health is unimaginable without a well-functioning immune system. In case it doesn´t work adequately in just one single detail, this will affect a person’s state of health sustainably – as the example of AIDS shows. Hence, the immune system is the most effective guarantor of our health, but still sometimes fails in its protective service, e. g. when encountering sudden mutations (cancer) or unknown molecules (autoimmune phenomena or allergies).
The present corona pandemic is currently a social challenge, but we can also take our intellectual lessons from it. The scientific community has now amassed detailed knowledge about the virus: All gene segments are known, the corresponding proteins, the 3D structures and functions, etc. And yet, after months, science and research are still perplexed by the great mystery of the virus is to be dealt with. The increasing number of people recovering from Covid-19 proves that the human immune system has long since solved this problem. THAT is ultimately the difference between human intelligence and the much more accomplished human immune system: I have not only observed this superiority of nature, but also used it in my work.
Treatments only with intention of symptom-relieving do not help sick people much. If properly instructed, our immune system will still fight any disorders most effectively: Under laboratory conditions it could be demonstrated that immune cells (or their products) – if primed correctly – display IRIS´s effect with amazing success in various diseases such as bronchial asthma, chronic viral infection e. g. genital warts, and even in CANCER.
It is known that immune and cancer cells are genetically almost identical, i. e. some sort of “siblings”. If one of these siblings gets off the right path (cancer!), its counterpart will rather try to bring him back on track instead of attacking or destroying. Our experiments in the lab and clinical observations support this notion. We subsume this phenomenon for cancer treatment under the term iREM (Immunological Re-Education of Malignancy):
In contrast to commonly applied destructive methods (e.g. chemotherapy, etc.), iREM follows an alternative way by transforming malignant tumor cells into benign ones by means of immunological instruction. In the course of a natural aging process, the “transformed” tumor cells gradually die. And although a tumor residue may still be conceivable right after completing the treatment, this is to be considered as harmless tissue only.
iREM means a personal, immunological treatment tailored to the needs of each patient; that is, no medication is used, but the treatment / recovery is based solely on the healing power of the patient’s own immune system. This should not be confused with the “personalized therapy” that is used by academic circles frequently, in which on the basis of genetic analysis most suitable selection of substances is identified from the portfolio provided by the pharmaceutical industry. The so-called immunotherapy, which is praised by academic circles, is actually nothing more than a type of chemotherapy with biological substances (cytokines, monoclonal antibodies) intended to destroy the tumor cells. Therefore, these two approaches are diametrically opposed to each other: personal (= immunologically based) therapy vs. personalized, but standardized (= industrialized) treatment.
Which patients may benefit from iREM?
A number of criteria are decisive for a successful treatment: Age, vitality, mobility, tumor load (amount), a reasonable life expectancy – and as little chemotherapy as possible: Such pre-treatment may result in various tumor mutations, which means that tumor cells may alter their characteristics or immunogenicity. In addition, iREM-trained immune cells are likely to be destroyed by cytostatic agents immediately upon re-injection. This, indeed, would probably undermine the expected success of iREM. Therefore, the best chances of curing are probably for “virgin”, i. e. not aggressively treated patients and not the terminal stage of cancer diseases, respectively.